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1. Introduction 
The introduction of new therapies has opened new therapeutic hopes in the field of treating 
Chronic Lymphocytic Leukemia (CLL). CLL is extremely heterogeneous in its clinical 
course; some patients live for decades with no need for treatment, whereas others develop 
aggressive clinical course with a survival of less than 2-3 years. The decision to treat CLL 
patients should be guided by clinical staging, the presence of symptoms and disease activity 
(Diehl et al. 1999). 
Once the diagnosis of CLL has been made, the treating physician is faced with the decision 
of not only how to treat the patient, but when to initiate therapy. In general practice, newly 
diagnosed patients with asymptomatic early-stage disease (Rai 0, Binet A) are monitored 
without therapy until they have evidence of disease progression. Studies from the French 
Cooperative Group on CLL, (Dighiero et al. 1998) the Cancer and Leukemia Group 
B,(Shustik et al. 1988) the Spanish Group PETHEMA, (Montserrat et al. 1996) and the 
Medical Research Council  (Catovsky et al. 1988) confirm that the use of alkylating agents in 
patients with early-stage disease does not prolong survival (Group. 1999). Patients at 
intermediate (I and II) or high-risk (III and IV) according to the modified Rai classification or 
Binet stage B or C usually require the initiation of treatment at presentation. Some of these 
patients (in particular Rai intermediate risk or Binet stage B) can still be monitored without 
therapy until they exhibit evidence of progressive or symptomatic disease. 
During the past decade there have been major advances in understanding the pathogenesis 
of the disease and more efficient treatments have been developed. CLL treatments have seen 
the transition from single-agent alkyator-based therapies to nucleoside analogs, combination 
chemotherapy, and recently to monoclonal antibodies (MAbs) and chemoimmunotherapy. 
The use of immunotherapy is emerging as an exciting modality with significant potential to 
advance the treatment of B-cell malignancies. In the field of lymphoproliferative diseases 
rituximab, followed by the anti-CD52 antibody alemtuzumab, has changed the therapeutic 
landscape of B-cell cancers, particularly in patients with non-Hodgkin’s lymphoma (NHL) 
with more recent indications in the setting of CLL (Cheson 2006). 
Novel therapies are being evaluated both in pre-clinical studies and in clinical trials. These 
treatments include new MAbs such as ofatumumab, GA101, veltuzumab, epratuzumab, 
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lumiliximab, TRU-016 as well as agents targeting the anti-apoptotic Bcl-2 family of proteins, 
antisense oligonucleotides and other agents. This review attempts to summarize the current 
knowledge of these treatments and point to potential opportunities in the future with other 
targeted therapies currently being explored. 
2. Best compounds of alkylating agents and purine analogs used in CLL 
Chlorambucil, an alkylating agent, has been considered the “gold standard” for several 
decades. Due to its low toxicity and its oral administration, this drug remains the 
appropriate option for non-fit, elderly patients as well as for younger fit patients. 
Chlorambucil achieved higher remission rates (Overall response rates (ORR) 89%, Complete 
responses (CR) 59%) when administered at a fixed dose of 15 mg daily up to achievement of 
a CR or occurrence of grade 3 toxicity, for a maximum of six months (Jaksic et al. 1997). 
However, chlorambucil is no longer considered an appropriate option for younger or 
physically fit patients because of its low to non-existent CR rate (Catovsky et al. 2007).  
Besides chlorambucil, cyclophosphamide (C) is another alkylating agent with activity in 
CLL patients. It is generally utilized in combination regimen. (Hansen et al. 1988; Raphael et 
al. 1991).  
Fludarabine is the best purine analog studied in CLL. When used as single agent, it achieves 
superior ORR and longer progression-free survival (PFS) rates compared with other 
treatment regimens containing alkylating agents or corticosteroids (Anaissie et al. 1998; 
Plunkett et al. 1993; Rai et al. 2000). In phase III studies in naive CLL patients, fludarabine 
induced more CRs (7–40%) as well as longer duration of remission than other 
chemotherapies or chlorambucil. However, overall survival (OS) was not improved by this 
drug when used as a single agent (Johnson et al. 1996; Leporrier et al. 2001; Rai et al. 2000; 
Steurer et al. 2006).  
Bendamustine, a hybrid of an alkylating nitrogen mustard group and a purine-like 
benzimidazole, has been used for more than 30 years in Germany. Results of a recent 
randomized trial, comparing bendamustine to chlorambucil, showed that more patients 
achieved CRs with bendamustine than with chlorambucil (31% vs. 2%). Moreover, the 
median PFS was 21.6 months and 8.3 months for bendamustine and chlorambucil, 
respectively (Knauf et al. 2009).   
3. Rituximab: The first anti-CD20 MAb 
Rituximab has revolutionized the therapeutic approach for patients with a wide variety of 
B-cell malignancies, including CLL. Rituximab is a chimeric human-mouse MAb with a high 
affinity for the CD20 surface antigen, a transmembrane protein that is expressed on pre-B 
cells and normal differentiated B lymphocytes. The predominant mechanism of action of 
rituximab-induced cell death is proposed to be primarily the result of antibody-dependent 
cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and direct 
cell death (Di Gaetano et al. 2003; Golay et al. 2000; Manches et al. 2003).  
Rituximab was first approved in the United States for the treatment of relapsed or 
refractory, low grade or follicular, B-cell NHL (Grillo-Lopez et al. 1999) then approved in 
Europe, for the treatment of relapsed stage III/IV follicular NHL (Gopal & Press 1999; 
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McLaughlin et al. 1998). In CLL, rituximab is less active as single agent than in other 
lymphomas, unless very high doses or denser dosing regimen are used. The objective 
response rates observed in CLL patients are ranged between 25% and 35% (Huhn et al. 2001; 
Itala et al. 2002).  
In contrast, the greatest benefit of rituximab is demonstrated when used in combination 
with chemotherapy. Multiple combinations are currently in use and others are in 
investigational phases. Here, we will present some of these combinations to highlight the 
synergistic effect of rituximab with other agents. 
The combination of fludarabine with rituximab prolonged the PFS and OS of CLL patients 
compared to fludarabine alone (Byrd et al. 2005). 
A phase II study performed by the German CLL Study Group (GCLLSG) of fludarabine and 
rituximab in both refractory and previously untreated patients resulted in an ORR of 87% 
with a subset achieving CR (Schulz et al. 2002). 
CALGB 9712 evaluated fludarabine in combination with rituximab given either concurrently 
or sequentially. Patients in the concurrent arm experienced more severe hematologic and 
infusion-related toxicity, but the ORR was 90% with a CR of 47% compared with an ORR of 
78% and CR of 28% in the sequential arm (Byrd et al. 2003). 
Likewise, rituximab induced a high ORR and complete remission rates when combined 
either with fludarabine/cyclophosphamide in refractory/relapsed CLL patients (73% and 
25%, respectively) (Wierda et al. 2005) or in those with previously untreated CLL (95% and 
72%, respectively) (Tam et al. 2008). The superiority of fludarabine, cyclophosphamide plus 
rituximab (FCR) compared to fludarabine and cyclophosphamide, alone was also confirmed 
in randomized phase III trials (Hallek 2008; Robak 2008; Tam et al. 2008). 
In the CLL8 protocol of the German CLL Study Group (GCLLSG), 817 treatment-naive, 
physically fit patients (aged 30–81 years) were randomly assigned to receive either 
fludarabine, cyclophosphamide, and rituximab (FCR group) or fludarabine and 
cyclophosphamide (FC group). At 3 years after randomization, 65% of patients in the FCR 
group were free of progression compared with 45% in the FC group (P < 0.0001); The three–
year survival rates were 87% and 83% for FCR–treatment and FC–treatment (p=0.012), 
respectively. FCR treatment was more frequently associated with hematologic adverse events, 
particularly neutropenia; these results suggest that the choice of FCR as first-line treatment 
prolongs OS of CLL patients (Hallek et al., 2010). 
Furthermore, when combined with pentostatin and cyclophosphamide in previously 
untreated CLL patients, rituximab achieved a significant clinical activity despite poor risk-
based prognoses, including achievement of minimal residual disease in some patients (Kay 
et al. 2007; Keating et al. 2005; Tam et al. 2006).   
The German CLL Study Group initiated two studies to explore the combination of 
bendamustine plus rituximab in patients with relapsed CLL (Fischer 2008) and in previously 
untreated CLL patients (Fischer 2009). Results showed an ORR of 77%, CR rate of 15% for 
relapsed patients and an OR of 91%, CR of 33% for untreated ones. A retrospective Italian 
study was conducted in 109 relapsed/refractory CLL patients. Results showed that the 
combination of rituxmab plus bendamustine was an effective and well-tolerated treatment 
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for these patients, producing a remarkable high CR rate and mild toxicity (Iannitto et al. 
2011). 
Investigations of the mechanism underlying the anti-tumor activity of rituximab as a single 
agent and in combination with chemotherapy are ongoing.  By understanding these 
mechanisms, it might be possible to further enhance current cell killing strategies or develop 
novel agents and strategies. 
4. Newer anti-CD20 antibodies for CLL 
4.1 Ofatumumab 
Ofatumumab is a fully humanized MAb targeting a small-loop CD20 epitope distinct from 
that of rituximab (Teeling et al. 2004). Compared to rituximab, it demonstrates an increased 
target-binding affinity to CD20 and slower dissociation rates. It exhibits stronger 
complement-mediated toxicity and shows potent lysis of rituximab-resistant cells.  
In phase I/II study in relapsed/refractory CLL patients, ofatumumab achieved an ORR of 
44%; however, these were almost exclusively partial responses (Coiffier et al. 2008). In a 
phase I/II dose-escalation trial, the efficacy and safety of single-agent ofatumumab (300-
1000 mg) have been evaluated in 40 patients with relapsed or refractory Follicular 
Lymphoma (FL). Rapid, efficient and sustained peripheral B-cell depletion was observed in 
all dose groups. The ORR in evaluable patients (n=36) was 43% (Hagenbeek et al. 2008). 
This antibody was recently approved by the Food and Drug Administration (FDA) for 
fludarabine and alemtuzumab refractory CLL patients and for fludarabine refractory 
patients with bulky disease. Ofatumumab was administered in these two groups with an 
ORR of 58% and 47%, respectively (Wierda G 2009). It is currently being combined with 
other agents in CLL, including bendamustine. 
A recently completed phase II trial of ofatumumab in combination with fludarabine and 
cyclophosphamide demonstrated CRs in up to 50% of patients with previously untreated 
CLL, despite poor prognostic factors (Wierda G 2009). The median PFS has not been reached 
with the short median follow-up of 8 months. 
Moreover, a randomized phase II study was conducted using two dose schedules of 
ofatumumab (500 mg and 1000 mg) in combination with fludarabine 25 mg/m2 and 
cyclophosphamide 250 mg/m2. The CR rate was 32% for the 500-mg and 50% for the 1000-
mg cohort; the ORR was 77% and 73%, respectively (Wierda et al. 2010). 
4.2 GA101 
GA101 is the first humanized type II anti-CD20 MAb with glycolengineered Fc portion and 
a modified elbow hinge (Bello & Sotomayor 2007). The adapted Fc region gives GA101 a 50-
fold higher binding affinity to FCγRIII (CD16) compared to a non-glycoengineered 
antibody, resulting in 10- to 100-fold increase in ADCC against CD20+ NHL cell lines via the 
activation of effector cells (Umana 2006). Moreover, the modified elbow hinge area also 
results in strong induction of direct cell death of several NHL cell lines and primary 
malignant B cells in vitro (Alduaij W & S. 2009; Bello & Sotomayor 2007; Umana 2006). 
However, these modifications result in reduced CDC activity (Umana 2007). In vitro B-cell 
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depletion assays with whole blood from healthy and leukemic patients showed that the 
combined activity of ADCC, CDC, and apoptosis for GA101 was significantly superior to 
rituximab (Alduaij W & S. 2009; Patz M 2009; Umana 2006; Zenzl 2009).  
The enhanced efficacy of GA101 has been also shown in vivo. In xenograft models of Diffuse 
large B-cell lymphoma (DLBCL ) and mantle cell lymphoma, treatment with GA101 resulted 
in CR and long-term survival compared with tumor stasis achieved with rituximab (Umana 
2006). In cynomolgus monkeys, GA101 (10 and 30 mg/kg infused on days 0 and 7) showed 
significantly superior depletion of B cells compared to rituximab (10 mg/kg) from day 9 to 
day 35 and was more efficacious at clearing B cells from lymph nodes and the spleen 
(Umana 2007).  
Initial phase I study of patients with relapsed/refractory CD20+ disease (n=21), including 
CLL, DLBCL, and other NHLs, for whom no therapy of higher priority was available (95% 
of patients had previously received rituximab), GA101 demonstrated a favorable safety 
profile with no dose-limiting toxicities (Salles 2009). The depletion of B-cell was rapid and 
sustained in the majority of patients. Nine of the evaluable patients responded to therapy 
(ORR, 43%; five CR/unconfirmed CR and four partial responses), with responses observed 
at all dose levels and across all FcγRIIIA genotypes. 
The pharmacokinetics of GA101 are generally similar to those of rituximab and dose- 
dependent. However, significant inter- and intra-patient variabilities have been observed, 
the clinical relevance of which will need further investigation [86]. Results from a phase I 
study in patients with previously treated B-CLL (n=13) who were given single-agent GA101 
(400–2000 mg; nine infusions) showed similar safety and pharmacokinetic profiles to those 
observed in the previously described patients with NHL, except for an increased incidence 
of neutropenia (Morschhauser 2009).  
GA101 is currently being explored as a single agent in phase II studies in 
relapsed/refractory B-CLL and indolent/aggressive NHL, and in combination with 
chemotherapy in a phase Ib study. 
4.3 Veltuzumab (IMMU-106) 
Veltuzumab is a humanized CD20 MAb (type I) constructed recombinantly on the 
framework regions of epratuzumab, with complementarity-determining regions (CDRs) 
identical to rituximab, except for a single amino acid in CDR3 of the variable heavy 
chain. It showed anti-proliferative, apoptotic, and ADCC effects in vitro similar to 
rituximab, but with significantly slower off-rates and increased CDC in several human 
lymphoma cell lines. In addition, at very low doses, given either intravenously or 
subcutaneously, veltuzumab showed a potent anti-B cell activity in cynomolgus 
monkeys and controlled tumor growth in mice bearing human lymphomas (Goldenberg 
et al. 2009). 
In a phase I/II dose-escalating clinical trial in patients with recurrent NHL, the ORR for 
veltuzumab-treatement was 41% (33/81), including 17 patients (21%) with CR or 
unconfirmed CR (Morschhauser et al. 2009). Veltuzumab caused B-cell depletion after the 
first infusion even at the lowest dose of 80 mg/m2, which persisted after the fourth infusion, 
and was well tolerated, with no evidence of immunogenicity. 
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Veltuzumab is additionally being developed for subcutaneous administration, which may 
provide advantages for this agent versus other MAbs (Goldenberg et al. 2010). Veltuzumab 
is undergoing clinical trials using a low-dose subcutaneous formulation in patients with 
NHL and CLL. 
5. Other MAbs for CLL 
5.1 Alemtuzumab 
Alemtuzumab is a recombinant, fully humanized, MAb targeting the CD52 antigen. CD52 is 
expressed on virtually all lymphocytes at various stages of differentiation, as well as monocytes, 
macrophages and eosinophils, whereas hematopoeitic stem cells, erythrocytes and platelets do 
not express it (Hale et al. 1990). A high level of CD52 is found on T-prolymphocytic leukemia, 
followed by B-CLL, with the lowest levels expressed on normal B cells. The mechanisms of 
action of alemtuzumab include CDC, ADCC and induction of apoptosis (Mone et al. 2006). 
The use of alemtuzumab monotherapy is approved in the United States in the first-line 
treatment of patients with CLL. In a pivotal phase II study in 93 patients with fludarabine-
refractory disease, alemtuzumab yielded an ORR of 33% with a median OS of 16 months 
(Keating et al. 2005). 
Alemtuzumab has been approved for the initial treatment of CLL based on randomized trial 
conducted including 297 patients who received either alemtuzumab or chlorambucil. The 
antibody induced an ORR rate of 83.2% with 24.2% CRs compared with 55.4% and 2%, for 
alemtuzumab and chlorambucil, respectively (Hillmen et al. 2007). In addition, 
alemtuzumab has proven efficacy even in patients with poor prognostic factors, including 
high-risk genetic markers such as deletions of chromosome 11 or 17 and p53 mutations 
(Lozanski et al. 2004; Stilgenbauer & Dohner 2002). The combination of alemtuzumab with 
fludarabine was investigated in a phase II trial with relapsed CLL patients. The ORR was 
83% including 30% CR (Elter et al. 2005). The combination of both alemtuzumab with 
rituximab has been also studied in patients with lymphoid malignancies including patients 
with refractory/relapsed CLL, producing an ORR of 52% with 8% CR (Faderl et al. 2003). 
The combination of fludarabine, cyclophosphamide plus alemtuzumab (FCA) was recently 
compared to fludarabine, cyclophosphamide plus rituximab (FCR) in a phase III study by 
“the french Cooperative Group On CLL and WM” (FCGCLL/MW) and “the Groupe Ouest-
est d’Etudes des Leucemies Aigues et Autres Maladies du Sang” (GOELAMS). Response 
rates of the first 100 patients were reported in a preliminary analysis with safety data 
presented for the entire cohort of 178 patients. The ORR in the first 100 patients was 96% for 
FCR compared to 85% in the FCA arm (p=0.086) with a CR rate of 78% in the FCR arm 
versus 58% in the FCA arm (p=0.072). Increased toxicity of FCA compared with FCR was 
found, preventing the use of the FCA combination outside of clinical trials (Lepretre 2009).  
5.2 Lumiliximab 
Lumiliximab is an anti-CD23 macque-human chimeric MAb with a strong similarity to the 
human antibody. The CD23 antigen is a low-affinity IgE receptor that is found in high levels 
in CLL patients (Fournier et al. 1992). Lumiliximab inhibits the IgE secretion in vitro, binds 
complement and mediates ADCC by binding FcγRI and RII receptors.  
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A phase I pilot study reported a limited single-agent activity in patients with 
refractory/relapsed CLL (Byrd et al. 2007b). Based on preclinical evidences of synergistic 
improvement of survival when lumiliximab was combined with fludarabine or rituximab, a 
phase I/II trial evaluated the safety and efficacy of lumiliximab in combination with FCR in 
31 patients of relapsed CLL patients (Byrd J 2008). This combination regimen yielded an 
ORR of 65%, which was comparable to the results seen with FCR in the pivotal phase II 
study conducted by the M.D. Anderson Cancer Center (Byrd J 2008; Wierda et al. 2005). 
Lumiliximab/FCR appeared to double the CR rate compared to FCR alone (52% vs. 25%) 
without increasing the rate of toxicities.  
5.3 Epratuzumab  
Epratuzumab is a humanized anti-CD22 MAb currently in clinical trials for treatment of 
NHL and autoimmune disorders (Leonard & Goldenberg 2007). Epratuzumab is selectively 
active against normal and neoplastic B-cells. This MAb acts as an immunomodulatory agent 
in contrast to rituximab which is an actually cytotoxic therapeutic antibody. In vitro, 
epratuzumab has demonstrated the ability to elicit ADCC and induce CD22 
phosphorylation and signaling, both of which may contribute as potential mechanisms of 
action (Carnahan et al. 2007; Carnahan et al. 2003).  
Phase I/II studies demonstrated objective responses across various dose levels in both 
relapsed/refractory FL (24%) (Leonard et al. 2003) and DLBCL (15%) (Leonard et al. 
2004). 
Epratuzumab has also been combined with rituximab in phase II studies showing at least 
an additive benefit while toxicities of the combination were comparable with those of 
single-agent rituximab (Leonard et al. 2005). In a recent international, multicenter trial 
evaluating rituximab plus epratuzumab in patients with post-chemotherapy 
relapsed/refractory, indolent NHL, an objective response was seen in 54% FL patients 
including 24% with CR/unconfirmed CR (CRu) whereas 57% of Small Lymphocytic 
Lymphoma patients had ORs including 43% with CR/Cru (Leonard et al. 2008). 
Rituximab-naive patients had an ORR of 50%, whereas patients who previously 
responded to rituximab had an ORR of 64%.  
Thus, the combination of epratuzumab and rituximab induced durable responses in patients 
with recurrent, indolent NHL. Epratuzumab is also being evaluated in combination with 
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and as 
a therapy in other B-cell neoplasms (Micallef et al. 2006). 
5.4 TRU-016 
TRU-016 is a CD37-directed small modular immunopharmaceutical protein composed of 
IgG1 variable regions (VL and VH) and a small, engineered constant region. CD37 is 
expressed at high concentrations on the surface of B cells and mature B-cell lymphomas and 
leukemias. In vitro studies demonstrated that the chimeric version of TRU-016 induced 
apoptosis and ADCC-dependent cytotoxicity in CLL cells (Zhao, Lapalombella et al. 2007). 
Interim results of a phase I study of TRU-016 reported a favorable toxicity profile and partial 
responses at higher doses (Andritsos 2009). 
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6. Emerging drugs 
6.1 Bcl-2 inhibitors 
The expression of high levels of anti-apoptotic Bcl-2 protein is characteristic of CLL cells 
(Hanada et al. 1993). Many studies have suggested that an increased ratio of anti- to pro-
apoptotic proteins such as Bcl-2/Bax is correlated with poor response to chemotherapy, 
disease progression and shorter survival (Pepper et al. 1997; Robertson et al. 1996). 
Modulation of anti-apoptotic proteins is a promising strategy to sensitize cells to 
antileukemic agents. Preclinical data have shown that inhibition of Bcl-2, inhibition of the 
interaction between Bcl-2 or Bcl-xL and partner proteins with compounds such as ABT-737 
(Mason et al. 2009) or inhibition of Mcl-1 were associated with increased sensitivity to 
antileukemic agents (Hallaert et al. 2007). 
Numerous novel agents have shown in vitro promise in overcoming the pro-apoptotic 
defects in CLL cells. These do not, however, always translate into a therapeutic in vivo 
effect.  
6.2 Oblimersen sodium (G3139) 
Oblimersen sodium is a phosphorothioate antisense oligodeoxynucleotide composed of 18 
nucleotides targeting the first six codons of the open reading frame of the bcl-2 mRNA. 
Preclinical evaluation has demonstrated good antineoplastic effect in B-cell cancers; several 
clinical trials have confirmed its safety and efficacy both alone and in combination with 
other therapeutics. 
A phase I/II clinical trial was conducted in patients with relapsed or refractory CLL to 
determine the maximum tolerated dose (MTD), efficacy, safety, and pharmacokinetics of 
oblimersen sodium. A total of 40 patients (who had received at least one prior 
chemotherapy regimen containing a purine analogue) were treated (14 in Phase I and 26 
in Phase II) with single-agent oblimersen sodium in doses ranging from 3 to 7 mg/kg/day 
in the phase I portion of the study. The MTD for the phase II part of the study was 
determined to be 3 mg/kg/day with higher doses of oblimersen sodium being associated 
with a cytokine release reaction characterized by fever, rigors and hypotension. This was 
attributed to the release of large amounts of cytokines. Thus, oblimersen sodium has 
shown a modest single-agent activity in heavily pretreated patients with advanced CLL 
(O'Brien et al. 2005). 
A phase II trial was conducted to evaluate the safety and efficacy of the combination of 
fludarabine, rituximab and oblimersen in previously untreated or relapsed/previously 
treated CLL patients. Preliminary results have been encouraging especially in the setting of 
CLL with poor prognostic markers (Marvromatis 2006; Mavromatis 2005). 
A randomized phase III trial of fludarabine and cyclophosphamide (FC) with or without 
oblimersen sodium in 241 patients with relapsed or refractory CLL who had received at 
least one prior fludarabine-containing regimen has been conducted. The rate of CR/nodular 
PR was significantly higher for patients treated with FC plus oblimersen, 17% versus 7%, 
respectively. The oblimersen treated group was associated with a significant survival benefit 
(O'Brien et al. 2007). 
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Overall, oblimersen has shown new hope and potential in the management of CLL, 
enhancing the efficacy of other commonly used agents.  Further studies with oblimersen 
should have a special focus on correlating response and survival outcomes with Bcl-2 
overexpression and subsequent decrease in Bcl-2 protein. 
6.3 Navitoclax (ABT-263) 
Navitoclax (ABT-263), a novel, orally bioavailable, small molecule, binds with high affinity 
to anti-apoptotic proteins Bcl-2, Bcl-xL, and Bcl-w, promoting apoptosis. In vitro, navitoclax 
shows potent targeted cytotoxicity against T and B lymphoid malignancies that over-express 
Bcl-2. A phase I trial demonstrated oral navitoclax monotherapy to be well-tolerated and to 
have anti-tumor activity in CLL patients.  
Phase II study was conducted in patients with heavily pretreated CLL, the drug attained an 
objective response rate of 33% (currently confirmed in 19% of patients); 58% of patients with 
baseline nodal enlargement showed shrinkage of greater than 50%.  
The combination of navitoclax with bendamustine/rituximab was effective for patients with 
relapsed or refractory CLL and presented encouraging results in a phase II trial. Moreover, 
phase III studies showed that the combination of navitoclax with 
fludarabine/cyclophosphamide/rituximab combination improved outcomes in CLL 
patients (Kipps 2010). 
6.4 Obatoclax (GX15-070) 
Obatoclax is a hydrophobic molecule, developed as a Bcl-2 family antagonist. This agent 
inhibits several anti-apoptotic Bcl-2 family proteins including Bcl-xL, Bcl-2, Bcl-w, BCL-B, 
A-1 and Mcl-1. It induces the release of Bak from Mcl-1, the liberation of Bim from both 
Bcl-2 and Mcl-1 as well as the formation of an active Bak/Bax complex. Moreover, it can 
promote the release of cytochrome c from mitochondria leading to apoptosis (Konopleva 
et al. 2008).  
A phase I trial of obatoclax was conducted in heavily pretreated patients with advanced 
CLL. Obatoclax was administered at doses ranging from 3.5 to 14 mg/m2 as a 1-hour 
infusion and from 20 to 40 mg/m2 as a 3-hour infusion every 3 weeks. Obatoclax 
demonstrated biologic as well as modest clinical activity in these patients with one (4%) of 
26 patients achieving a partial response (O'Brien et al. 2009). 
7. Newer treatment options 
7.1 Lenalidomide 
The immunomodulatory agent lenalidomide has shown activity in CLL in the 
relapsed/refractory as well as in the untreated setting. 
Activity in CLL was first demonstrated by Chanan-Khan et al. in a phase II study. 25 mg of 
lenalidomide was administered in this trial daily on days 1 through 21 of a 28-day cycle in 
45 pretreated CLL patients (Chanan-Khan et al. 2006). This regimen was associated with a 
47% ORR and a 9% CR rate.  
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Ferrajoli et al. adopted this dose escalation scheme in 45 patients with relapsed CLL. The 
dosing started at 10 mg daily for 28 days, with dose escalation to a maximum of 25 mg/day 
as tolerated. The ORR was 32% with 7% of patients achieving a CR (Ferrajoli et al. 2008). 
Moreover, lenalidomide therapy was well tolerated and induced durable remissions in 
elderly patients with CLL (Badoux et al. 2011). 
The combination of lenalidomide plus rituximab is currently being investigated in 60 
patients with relapsed CLL patients. 37 patients are to date evaluable for response. The ORR 
was 68%, no CR was achieved. The results obtained suggest that the combination of 
rituximab and lenalidomide is superior to the single agent lenalidomide.  
Currently, a study is recruiting participants to evaluate the combination of fludarabine plus 
rituximab with or without lenalidomide or cyclophosphamide in treating patients with 
symptomatic CLL.  
7.2 Flavopiridol (Alvocidib) 
Flavopiridol, a synthetic flavon, induces apoptosis in CLL cell lines by targeting cyclin-
dependent kinases. 
It shows high activity in CLL patients with relapsed high-risk CLL (Byrd et al. 2007a; Phelps 
et al. 2009). A phase II trial on relapsed CLL patients with genetically high risk features 
achieved an ORR of 53%, including one CR (Lin et al. 2009). Currently, a registration trial for 
flavopiridol in relapsed CLL is conducted in the United States and Europe. 
8. Conclusion 
A refreshing change is taking place in CLL research. There is an increasing interest to fully 
understand all subsets of CLL patients in order to develop novel and specific agents which 
cater to individualized needs of each subset. Currently available therapies are only partially 
efficient in CLL; thus, obvious clinical and scientific needs to develop new therapeutic 
options are under investigation to circumvent the limitations of currently used therapies in 
CLL. 
Further studies should elucidate the role of these new agents and their combinations in the 
management of CLL. 
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